Biogen’s New Alzheimer’s Drug Meets Slow Rollout - The Wall Street Journal

1. Biogen’s New Alzheimer’s Drug Meets Slow Rollout  The Wall Street Journal
2. Biogen's Aduhelm sales fall dramatically below Wall Street's expectations  STAT
3. Biogen sells just $300,000 worth of contentious Alzheimer’s drug  Financial Times
4. Biogen making layoffs in Raleigh, cites delay in Alzheimer’s drug access, new tech  WRAL Tech Wire
5. Biogen’s Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock.  Barron's
6. View Full Coverage on Google News

from Top stories - Google News https://ift.tt/eA8V8J